522 articles in this topic
Cardiovascular-kidney-metabolic syndrome affects nearly all US adults. A staged intervention model offers a roadmap from early risk to advanced disease.
A new study reveals SERPINE1 drives ferroptosis in ARDS by collapsing NAD+/NADH balance and silencing the longevity-linked Sirt3 enzyme.
A new framework shows how food structure, not just nutrients, can activate the gut's satiety cascade and boost endogenous GLP-1 naturally.
GLP-1 receptor agonists carry a 3.3x greater risk of hair loss than placebo. New guidance covers mechanisms, prevention, and management.
Researchers identify HDAC5 as the molecular switch inside beta cells that explains how alternate day fasting improves glucose metabolism.
A systems model reveals tirzepatide's edge over semaglutide comes from suppressing liver glucose output, not boosting insulin — reshaping T2D treatment strategy.
A 97,993-patient study finds tirzepatide lowers periodontitis, tooth loss, and oral infection risk compared to GLP-1 receptor agonists.
Machine learning applied to CT imaging uncovers a lean-but-metabolically-troubled fat phenotype that standard BMI assessment misses.
72-week data from SURMOUNT-J show tirzepatide dramatically reduces visceral adipose tissue and improves insulin sensitivity in non-diabetic Japanese adults.
Depleted hepatic glutamine drives CD4+ T cell-mediated liver damage in MASLD — and restoring it may offer a targeted therapy.
A 388-patient real-world study finds GLP-1 receptor agonists drive fat loss — especially visceral fat — with only modest muscle reduction over 6 months.
A natural fenugreek compound restores mitochondrial health and autophagy in diabetic kidney cells via a newly identified protein target.
